Algorithms of Patient Selection for Allergen Immunotherapy Authors: U Petra Zieglmayer, Stefania Arasi, Thomas Eiwegger, Thilo Jakob, Ludger Klimek, Markus Ollert Published: 2026 Abbreviations allergic asthma allergic conjunctivitis atopic dermatitis allergen immunotherapy allergic rhinitis basophil activation test eosinophilic esophagitis immunotherapy Molecular allergy diagnosis oral food challenge quality of life allergen‐specific IgE antibody skin prick test severity grade according to Ring & Meßmer [1] venom immunotherapy Allergen immunotherapy (AIT) remains the only disease‐modifying treatment for IgE‐mediated allergic diseases, providing long‐term symptom relief and preventing disease progression. Despite a century of clinical experience, patient selection for AIT continues to challenge clinicians, particularly when balancing diagnostic precision, expected efficacy, safety, and patient preference. Building on recent advances in diagnostics and consensus recommendations, this article outlines a pragmatic algorithm for selecting patients suitable for AIT across respiratory, food, and venom allergies. AIT decision‐making is multifactorial and relies on accurate diagnosis with regards to consistent clinical history corroborated by allergen sensitization and consideration of patient‐specific factors as well as the availability of high‐quality AIT products. Severity grading [1], frequency of exposure, and risk of future reactions guide the next step of therapeutic consideration. The formalization of diagnostic and therapeutic pathways has proven valuable across allergy disciplines. These approaches emphasize transparency, reproducibility, and individualized care. The integration of such algorithmic frameworks into clinical practice aims to optimize AIT indication, minimize inappropriate prescriptions, and ensure treatment success. Of note, patient adherence to AIT treatment is crucial, and therefore a shared decision taking into consideration patient's values and preferences is mandatory for improving clinical outcomes and enhancing patient engagement. In patients suffering from quality of life (Qol) impairing moderate to severe IgE‐mediated reactions against airborne allergen sources, polysensitization is common. Efficacy of AIT is in general specifically linked to the allergen source treated with. Thus, evaluation and denomination of clinically most relevant triggers is key. Correlation of IgE sensitization profiles with clinical disease can be challenging. Molecular allergy diagnostics help to differentiate between genuine and cross‐reactive in vitro and in vivo response. Clinical relevance must be determined by means of provocation testing if not clarified by standard testing (Figure 1) [2]. Algorithm of AIT indication process in patients suffering from symptoms due to sensitization against inhalative allergen sources. AA, allergic asthma; AC, allergic conjunctivitis; AD, atopic dermatitis; AIT, allergen immunotherapy; AR, allergic rhinitis; SPT, skin prick test; sIgE, allergen‐specific IgE antibody. On the basis of phase 3 clinical trials and real‐world experience, guidelines on food allergy management support implementing oral immunotherapy (OIT) into routine clinical practice [3, 4]. After a preliminary proper diagnosis and identification of clinically relevant food allergen sources (Figure 2), a shared decision‐making approach has to explore patient's goals and preferences, as well as a thorough review of potential alternatives in case of side effects of very low threshold reactions (e.g., omalizumab in combination with OIT or as monotherapy) – according to local available therapeutic options, outcomes, benefits, and risks. Counseling patients is imperative for the management of side effects [5]. In order to minimize the latter, mitigation strategies are under investigation including low dose protocols, commencement in below the age of 12 months [6, 7] and alternative routes of administration (e.g., epicutaneous or sublingual) [8]. Diagnostic workup in patients with suspected food allergy. BAT, basophil activation test; EoE, eosinophilic esophagitis; IT, immunotherapy; OFC, oral food challenge; QoL, quality of life; SG, severity grade according to Ring & Meßmer; SPT, skin prick test; sIgE, allergen‐specific IgE antibody. In insect venom allergy, clinical identification of the culprit insect after a systemic sting reaction is often not possible. Double‐positivity against honeybee venom and wasp (yellow jacket) occurs in up to 50% of patients [9]. Molecular allergy diagnosis (MA) facilitates a precise identification of the culprit insect (Figure S1) [10, 11], in particular in patients that did not identify the culprit insect. In addition, the ratio between sIgE levels to different venoms can be used as a marker indicative of recent venom exposure, in particular when MA is not available [12]. In certain regions (e.g., Southern Europe), double sensitization to Vespula and Polistes venoms is very frequent and diagnostic tools including MA are not always sufficient to identify the culprit insect [10, 11]. Specific IgE inhibition testing offers a potential solution in cases of Polistes‐Vespula double‐positivity, as the method may allow the identification of the culprit insect by inhibiting cross‐ reactive IgE reactivity against the other insect and distinction between cross‐reactivity and true double sensitization [10, 11]. When sIgE values are below detection limit despite a history of severe anaphylaxis, the basophil activation test (BAT) provides an additional sensitive test option [11]. However, both methods are costly and require specialized infrastructure and are therefore not subject to clinical routine use. Due to new evidence regarding co‐factors contributing to disease severity and the fact that successful application of AIT can be lifesaving in anaphylactic patients, some traditional contraindications were recently omitted or at least moved from “absolute” to “relative.” Nevertheless, management of restrictive conditions must be considered ahead of AIT prescription and during the course of treatment (Table S1) [5, 13]. Food allergy immunotherapy, specifically OIT, is generally contraindicated in patients with uncontrolled or severe asthma, active eosinophilic esophagitis (EoE), or other eosinophilic gastrointestinal diseases. Other significant contraindications include the use of beta‐blockers, severe cardiovascular disease, and poor compliance/adherence to recommendations due to potential side effects and risks in side effect management, malignancies, and severe autoimmune diseases due to a lack of evidence and due to theoretical considerations. Patients bearing a higher risk of anaphylactic reactions due to elevated basal mast cell tryptase (e.g., due to mastocytosis, alpha‐tryptasaemia, or cKIT mutations) require specific counseling before starting AIT [9]. In patients with insect sting anaphylaxis and confirmed mastocytosis, an increased VIT maintenance is recommended that should be applied prolonged or even lifelong. In cases that show systemic reactions during updosing or maintenance VIT, anti‐IgE treatment such as Omalizumab should be considered as off‐label add‐on treatment. In conclusion, a structured, algorithm‐driven approach enhances precision in selecting candidates for allergen immunotherapy. By integrating diagnostic advances, guideline recommendations, and patient‐centered care principles, clinicians can optimize outcomes and resource use. The future of AIT lies not merely in improved formulations but in systematic, individualized decision‐making supported by pragmatic clinical algorithms. Funding The authors have nothing to report. Conflicts of Interest P.Z. reports lecture fees from Alk Abelló, Allergopharma, Allergy Therapeutics, Bencard, HAL, Leti, MadX, Meda, Merck, Novartis, Stallergenes Greer, and ThermoFisher Scientific and honoraria for advisory board activities from Alk Abelló, Bencard, HAL, Meda, Medrrck, Novartis, Sigmapharm, and Stallergenes Greer. S.A. declares that she has participated as an advisory board member, and/or consultant, and/or speaker/chair at scientific meetings for Aimmune, DBV, Ferrero, Mabylon, Novartis, Stallergenes Greer, Thermo Fisher Scientific and Ulrich. Funded research (Institution) from Italian Minister of Health and Italian Minister of Education. All of this outside the submitted work. T.E. reports to have acted or acts as local PI for company‐sponsored trials by DBV Therapeutics, Greer‐Stallergens, Novartis, and sub‐investigator ALK‐Abelló. He is Co‐Investigator or scientific lead in three investigator‐initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program and serves as an associate editor for Allergy. He/his lab received unconditional/in‐kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK‐Abelló. He holds scientific advisory board roles for ALK‐Abelló, VAMED, Nutricia/Danone, Hipp, Sanofi, Greer‐Stallergens, Allergy Therapeutics, and Aimmune. T.E. reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, Sanofi, Schwalbe, MADX, and ALK‐Abelló. T.J. reports lecture fees from Alk Abelló, Allergy Therapeutics, Bencard, HAL, Leo, Novartis, and ThermoFisher Scientific, honoraria for advisory boards from Alk Abelló, Bencard, Galderma, Leo, and Novartis and research grants from Allergopharma, Germany, ALK‐Abello, Denmark, Novartis, Germany and Thermo Fisher Scientific/Phadia, Germany. T.J. is board member of the German Society of Allergy and Clinicial Immunology (DGAKI) and the German Society of Dermatology (DDG) and is Editor‐in‐Chief of the AllergoJournal and AllergoJournal International. L.K. has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK‐Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden; Bionorica, Germany; BioNTech, Germany; Biomay, Austria; Blueprint, USA; Boehringer Ingelheim, Germany; Celltrion, South Korea; Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland; Leti, Spain; Roxall, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA; and/or has served on the speaker's bureau or was consulting for the above mentioned pharmaceutical companies. L.K. is the current President of German Society of Allergology AeDA, Governance Committee Board Member and ENT Section Board Member of the European Academy for Allergy and Clinical Immunology (EAACI), Vice‐President of German Academy for Allergy and Environmental Medicine and Editor‐in‐Chief of AllergoJournal and AllergoJournal International. M.O. received lecture fees and/or research support and/or scientific consulting fees from Allergy Therapeutics/Bencard, Angany Inc., European Commission Horizon Europe, Hycor Diagnostics, Luxembourg National Research Fund FNR, Stallergenes Greer, and Thermo Fisher Scientific/Phadia. M.O. was Vice‐President Science of EAACI (2022–2024) and is Editor‐in‐Chief of EAACI‐3H Research and Innovation Hub. Supporting information Figure S1: Algorithm of decision‐making in patients with suspected insect venom allergy in geographic regions with exposure to honeybees, Vespula species (wasps/yellow jackets), and Polistes species as the main culprit insects. MA is first line diagnostics today, skin testing can be omitted if an unequivocal diagnosis is obtained by in vitro diagnostics. BAT, basophil activation test; QoL, quality of life; SG, severity grade according to Ring & Meßmer [1]; sIgE, allergen‐ specific IgE antibody; VIT, venom immunotherapy. Table S1: Contraindictions for AIT. Acknowledgments P.Z. developed the first draft of the manuscript. All other authors contributed equally to the work and are listed in alphabetical order. Open Access funding provided by Karl Landsteiner Privatuniversitat fur Gesundheitswissenschaften GmbH/KEMÖ. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study. References Associated Data Supplementary Materials Figure S1: Algorithm of decision‐making in patients with suspected insect venom allergy in geographic regions with exposure to honeybees, Vespula species (wasps/yellow jackets), and Polistes species as the main culprit insects. MA is first line diagnostics today, skin testing can be omitted if an unequivocal diagnosis is obtained by in vitro diagnostics. BAT, basophil activation test; QoL, quality of life; SG, severity grade according to Ring & Meßmer [1]; sIgE, allergen‐ specific IgE antibody; VIT, venom immunotherapy. Table S1: Contraindictions for AIT. Data Availability Statement Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.